Neurotrack develops digital cognitive assessment tools designed to screen for dementia and Alzheimer’s disease risk using eye-tracking technology. The company’s platform delivers fast, non-invasive assessments that can be administered on standard digital devices. Its approach focuses on objective measurement of cognitive function rather than self-reported symptoms. Neurotrack positions its technology within clinical screening and research contexts.

The technology uses eye-tracking to measure visual attention, memory encoding, and recognition patterns during short cognitive tasks. AI-driven models analyze these eye-movement signals to identify biomarkers associated with early cognitive impairment. Because assessments can be completed quickly and without specialized hardware, the platform supports scalable and repeatable screening. This approach emphasizes sensitivity to subtle cognitive changes that may precede overt symptoms.

Neurotrack targets early detection and risk screening for dementia and Alzheimer’s disease in clinical, research, and population health settings. The platform is intended to support clinicians and healthcare systems by enabling earlier identification of at-risk individuals. Its positioning reflects growing interest in digital, objective cognitive biomarkers that can improve access to preventive neurological care.